Preserving What's Vital to Life

Red blood cells are vital to life, and every transfusion is vital to a patient.

By preserving the viability of red blood cells, Hemanext’s goal is to help every transfusion do more for every patient.

Discover Hemanext ONE® Explore the Science
Redefining Transfusion Medicine

Every day, transfusions save lives. Yet the quality of stored red blood cells (RBC) can decline over time and affect their ability to deliver oxygen to patients.1

Hemanext has reimagined blood storage with oxygen-controlled technology that preserves RBC function, which may help hospitals and clinicians provide the highest quality transfusion care.1–3

What We Do

The Science of Blood Storage

When RBC are exposed to oxygen during storage, they develop progressive damage collectively labeled as storage lesions. Storage lesions are the collection of metabolic, biochemical and structural changes to RBC during refrigerated storage that reduce their flexibility, oxygen delivery ability and energy production.4–7

For patients who depend on regular transfusions, RBC degradation means lower incremental increase in Hb per unit, more rapid Hb decline, and increased iron burden over time.9–13

Learn more

The Hemanext ONE® Solution

Hemanext ONE is an oxygen-controlled processing and storage system that removes oxygen from red blood cell units during processing and maintains that low oxygen environment throughout refrigerated storage.

By controlling oxygen exposure from processing to day 42, Hemanext ONE helps preserve red cell quality parameters, including membrane integrity, deformability, and metabolic stability—supporting a more consistent and higher-quality RBC product for transfusion.1–3,14–16

Discover the Technology

The Benefits

By reducing oxidative damage during storage, Hemanext ONE preserves the viability of red blood cells—keeping them structurally, functionally, and metabolically closer to its natural state within the body. The result: higher-quality blood, consistent performance, and potentially improved transfusion outcomes.1–3,6,15

See the Advantages
Why It Matters

Transforming Chronic Transfusion Care

Patients who require lifelong transfusions need more than routine red blood cells (RBC). They need consistency, durability, and to have fewer complications over time. By reducing oxygen before storage, Hemanext ONE preserves RBC metabolism, reduces hemolysis and iron release, and potentially supports more effective, longer-lasting transfusion effects.1–3,8,9

Explore how Hemanext ONE can help chronically transfused patients

High-Performance Blood for Critical Resuscitation

Trauma patients often need blood transfusions urgently or emergently to restore oxygen delivery and improve hemodynamics. In preclinical models of hemorrhagic shock, oxygen-controlled red blood cells improved cardiac function, reduced organ injury, and achieved the same physiologic recovery with roughly half the transfusion volume required by conventional blood.15

Learn how Hemanext ONE supports faster, more effective resuscitation

For Blood Establishments: Deliver Higher-Quality Red Cells

Blood centers aim to provide hospitals with the safest, highest-performing units possible. With Hemanext ONE, partners can offer oxygen-controlled red blood cells that stay viable longer and potentially achieve better transfusion outcomes, which may elevate the standard of care across every unit delivered.1–3

Partner With Us
News, Guidance & Next Steps

Latest News & Insights

Stay informed about Hemanext’s latest progress—from research milestones and clinical collaborations to conference participation and industry recognition.

View All News

U.S. Reimbursement & Coding

Hemanext ONE red blood cells are recognized by the CMS with a HCPCS Level II code for “Red blood cells, leukocytes reduced, oxygen/carbon dioxide reduced, each unit”, also known as oxygen-controlled RBC units.17

The outpatient reimbursement rate for oxygen-controlled RBC is set at nearly three times higher than that for conventional RBC, reflecting the innovation and added clinical value of oxygen-controlled storage.

Learn About U.S. Reimbursement

Start Using Hemanext ONE

We’re here to help you integrate oxygen-controlled red blood cell storage into clinical practice. Reach out for ordering guidance, availability, and support from our team of specialists.

Contact Us to Order
Preserving What's Vital to Life
  1. Rabcuka J, Blonski S, Meli A, et al. Metabolic reprograming under hypoxic storage preserves faster oxygen unloading from stored red blood cells. Blood Adv. 2022; 6(18):5415-5428. Doi: 10.1182/bloodadvances.2022007774.
  2. Karafin MS, Field J, Ilich A, et al. Hypoxic storage of donor red cells preserves deformability after exposure to plasma from adults with sickle cell disease. Transfusion. 2022;1-10. Doi: 10.1111/trf.17163.
  3. D’Alessandro A, Yoshida T, Nestheide S, et al. Hypoxic storage of red blood cells improves metabolism and post-transfusion recovery. Transfusion. 2020;60(4):786-798.
  4. Mustafa I, Al Marwani A, Mamdouh Nasr K, Abdulla Kano N, and Hadwan T. Time dependent assessment of morphological changes: leukodepleted packed red blood cells stored in SAGM. BioMed Research Intl. 2016:4529434. Doi: 10.1155/2016/4529434.
  5. Orlov D and Karkouti K. The pathophysiology and consequences of red blood cell storage. Anesthesia 2015;70 (Suppl. 1).: 29-37. Doi:10.1111/anae.12891.
  6. Yoshida T and Shevkoplyas SS. Anaerobic storage of red blood cells. Blood Transfus 2010;8:220-36. Doi: 10.2450/2010.0022-10.
  7. Kim-Shapiro D, Lee J, and Gladwin M. Storage lesion. Role of red cell breakdown. Transfusion. 2011;51(4):844-851.
  8. Rapido F, Brittenham G, Bandyopadyay S, et l. Prolonged red cell storage before transfusion increases extravascular hemolysis. J Clin Invest. 2017;127(1):375-382. Doi:10.1172/JCI90837.
  9. Hod EA, Zhang N, Sokol SA, et al. Transfusion of red blood cells after prolonged storage produces harmful effects that are mediated by iron and inflammation. Blood. 2010;115(21):4284-92. Doi: 10.1182/blood-2009-10-245001.
  10. Carter P and Dunham A. Modelling haemoglobin incremental loss on chronic red blood cell transfusions. Vox Sanguinis. 2022;1-8. Doi: 10.1111/vox.13261.
  11. Carter P and Dunham A. Modeling hemoglobin levels of patients chronically transfused with red blood cells. Transfusion. 2023;1-8. Doi: 10.1111/trf.17305.
  12. Hunsicker O, Hessler K, Krannich A, et al. Duration of storage influences the hemoglobin rising effect of red blood cells in patients undergoing major abdominal surgery. Transfusion. 2018;58(8):1870-1880. Doi: 10.1111/trf.14627.
  13. Rydén J, Clements M, Hellström-Lindberg E, et al. A longer duration of red blood cell storage is associated with a lower hemoglobin increase after blood transfusion: a cohort study. Transfusion. 2019;59:1945-1952. Doi: 10.1111/trf.15215.
  14. Dumont LJ, Yoshida T, AuBuchon JP. Anaerobic storage of red blood cells in a novel additive solution improves in vivo recovery. Transfusion. 2009;49(3):458-64.
  15. Williams AT, Jani VP, Nemkov T, et al. Transfusion of anaerobically or conventionally stored blood after hemorrhagic shock. Shock. 2020;53(3):352-362.
  16. Rabcuka J, Fallon J, Meli A, et al. Storage under hypoxia improves the ability of red cells to release oxygen in ex vivo perfused human kidneys. Blood Red Cells & Iron. 2025. Doi: /10.1016/j.brci.2025.100038.
  17. HCPCS Level II Coding Decisions. CMS.gov. Published October 7, 2024. Accessed December 12, 2025. https://www.cms.gov/files/document/2024-hcpcs-application-summary-biannual-1-2024-non-drug-and-non-biological-items-and-services.pdf.

By producing higher quality RBCs, the Hemanext ONE system has the potential to enable fewer and more effective transfusions for patients. I am truly excited by the possibility of bringing this improved red blood cell replacement therapy to populations in the U.S. that have been waiting for a transformative technology like this one.

Dr. Philip C. Spinella
Professor, Department of Surgery and Department of Critical Care Medicine at University of Pittsburgh

We value our partnership with Hemanext to enhance blood product quality and availability. Hemanext ONE has the potential to strengthen the resiliency of the blood supply, and this FDA authorization is a significant milestone to that end.

Ralph Vassallo, MD, FACP
Executive Vice President, Chief Medical and Scientific Officer of Vitalant

The Hemanext ONE system offers promise to improve the treatment landscape for patients burdened by transfusions and could be an essential step towards performing fewer and better transfusions. Having long championed Hemanext’s transformative initiatives, I eagerly anticipate witnessing the positive influence, right here in the United States, on the advancement of transfusion therapy quality.

Paul M. Ness, MD
Former Director, Division of Transfusion Medicine at Johns Hopkins University and board member of Hemanext

By deoxygenating red cells and maintaining them in their hypoxic state throughout storage, the resulting red cells experience less oxidative stress and oxidative damage, have improved metabolism, and are also more deformable leading to improved micro vascular profusion and less hemolysis.

Dr. Steven Spitalnik, MD
Co-Director of the Laboratory of Transfusion Biology, Colombia University

The preclinical data by Williams et al. show anaerobically stored RBCs achieve multiple clinically important functional resuscitation goals, with a smaller volume of fluid and the FDA benchmark of 24-hour RBC recovery. I look forward to the clinical trials in bleeding patients.

John Holcomb, MD, FACS
University of Alabama at Birmingham

I have had several patients who have received Hemanext hypoxic blood, and several of the patients have personally said thanks for having been given the opportunity and also that they have felt better after transfusion with hypoxic blood compared to conventional transfusion. One must of course be careful not to attach too much importance to such observations, but I would still like to mention that there has been a remarkable tendency towards this.

Håkon Reikvam, MD, PhD
Professor, Department of Clinical Science, University of Bergen, Norway

CONTACT US  |  TERMS OF USE

PRIVACY & COOKIES POLICY

This website may contain information on products or uses of those products that are not authorized in all countries or regions. Hemanext ONE has been granted marketing authorization for commercial distribution via the De Novo process by the U.S. Food & Drug Administration. In Europe Hemanext ONE is CE marked which allows the medical device to be placed in the market in the EEA. Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Hemanext, Hemanext ONE, and the logos are registered trademarks of Hemanext, Inc. © 2026 Hemanext, Inc. All rights reserved.

Contact Us